title: [Targeted therapy in locally and metastatic recurrent cervical cancers].
abstract: Doublet chemotherapy with cisplatin is the reference for the treatment of recurrent cervical cancer. However, those tumors are little chemo-sensitive and overall survival remains poor. Moreover, because of pelvic irradiation, toxicities, especially hematologic toxicities, are increased and require a drug dose reduction. Finally, these treatments are rarely effective in radiation areas. Given all these elements, the development of new therapies is a prominent issue. This article reviews the results of the major targeted therapies in cervical cancer. Anti-EGFRs are disappointing despite of a strong biological rational. On the other hand, bevacizumab is the first targeted therapy to show a significant increase of overall survival. A major effort must be made in translational research for a better understanding of tumor biology of these tumors.
authors.affiliation: Institut Curie, site Paris, Département d'oncologie médicale, 26, rue d'Ulm, 75248 Paris cedex 05, France.
authors.forename: Romain
authors.initials: R
authors.lastname: Geiss
authors.affiliation: Institut Curie, site Saint-Cloud, Département d'oncologie médicale, 35, rue Dailly, 92210 Saint-Cloud, France.
authors.forename: Thibault
authors.initials: T
authors.lastname: De La Motte Rouge
authors.affiliation: Institut Curie, site Saint-Cloud, Département d'oncologie médicale, 35, rue Dailly, 92210 Saint-Cloud, France.
authors.forename: Coraline
authors.initials: C
authors.lastname: Dubot
authors.affiliation: Gustave-Roussy, Département d'oncologie médicale, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Leary
authors.affiliation: Gustave-Roussy, Département d'oncologie médicale, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Lhommé
authors.affiliation: Gustave-Roussy, Département d'oncologie médicale, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
authors.forename: Patricia
authors.initials: P
authors.lastname: Pautier
authors.affiliation: Institut Curie, site Paris, Département d'oncologie médicale, 26, rue d'Ulm, 75248 Paris cedex 05, France.
authors.forename: Suzy
authors.initials: S
authors.lastname: Scholl
authors.affiliation: Institut Curie, site Paris, Département d'oncologie médicale, 26, rue d'Ulm, 75248 Paris cedex 05, France, Université Paris Descartes, 12, rue de l'École-de-Médecine, 75270 Paris cedex 06, France.
authors.forename: Manuel Jorge
authors.initials: MJ
authors.lastname: Rodrigues
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases
keywords: EGFR; bevacizumab; cervical cancer; targeted therapy